Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Liraglutide: a once-daily GLP-1 analogue for the treatment of type 2 diabetes mellitus

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Will novel oral formulations change the management of inflammatory bowel disease?

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Mometasone furoate nasal spray for the treatment of asthma

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Lixisenatide for type 2 diabetes mellitus

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Serotonin 2A receptor antagonists for treatment of schizophrenia

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. Hepatic microbiome in healthy lean and obese humans

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Pancreatic polypeptide: A potential biomarker of glucose-dependent insulinotropic polypeptide receptor activation in vivo

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Acute hypoglycemia and risk of cardiac arrhythmias in insulin-treated type 2 diabetes and controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  4. Expression of cholecystokinin and its receptors in the intestinal tract of type 2 diabetes patients and healthy controls

    Research output: Contribution to journalJournal articleResearchpeer-review

  5. Effects of endogenous GIP in patients with type 2 diabetes

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations
The incretin hormones are intestinal peptides that enhance insulin secretion following ingestion of nutrients. Liraglutide is a glucagon-like peptide-1 receptor analogue, which is obtained by derivatising glucagon-like peptide-1 with a fatty acid, providing a compound with pharmacokinetic properties that are suitable for once-daily dosing. Liraglutide has demonstrated lasting improvement of HbA(1c )levels, weight reduction and improved beta-cell function in patients with Type 2 diabetes mellitus. Liraglutide is well tolerated; the adverse events that are most frequently reported being transient nausea and diarrhoea. This article reviews the mechanisms of action and efficacy of liraglutide for the treatment of Type 2 diabetes mellitus. This agent is presently in Phase III clinical development.
Original languageEnglish
JournalExpert Opinion on Investigational Drugs
Volume16
Issue number2
Pages (from-to)231-7
Number of pages7
ISSN1354-3784
DOIs
Publication statusPublished - 1 Feb 2007

ID: 32268071